Navigation Links
Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
Date:3/28/2013

1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will submit a CTA for OMS721 and begin clinical trials; that OMS721 may be delivered subcutaneously and the frequency of dosing; the diseases that may be treated by OMS721; the potential competitive advantages of OMS721; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015   AMC ... management solutions recognized for improving the effectiveness and ... that Robert Anazagasty and Jared ... serve as Vice President, Strategic Client Development, and ... These additions support AMC Health,s commitment to accelerating ...
(Date:3/5/2015)... -- LUNGevity Foundation, the nation,s leading lung cancer ... approval of Bristol Myers Squibb,s new immunotherapy drug ... another critical new treatment option to fight lung ... own immune system to fight cancerous cells. Importantly, ... with squamous cell lung cancer, a population for ...
(Date:3/5/2015)... PRINCETON, N.J. , March 5, 2015 ... late stage biopharmaceutical company committed to developing products that ... oncology and biodefense, announced today that its President and ... will give a corporate presentation at the 27 th ... California , on Tuesday, March 10, 2015 at ...
Breaking Medicine Technology:AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
... clinical research data suggests that [18F] Flutemetamol could add ... provide accurate identification of beta amyloid plaques, considered to ... (AD).  Flutemetamol, a GE Healthcare Positron Emission Tomography (PET) ... studied to identify the uptake of beta amyloid via ...
... 13, 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... received approval from the U.S. Food and Drug Administration ... ) Injection, the Company,s product used to treat acetaminophen ... Ethylene diamine tetracetic acid or any other stabilization and ...
Cached Medicine Technology:GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 3Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 2Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 3Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 4
(Date:3/6/2015)... Dr. Mark Sowell recently returned from leading a three day ... advanced education in the field of dentistry, Spear Education draws ... visiting faculty member of this prestigious institution, Dr. Sowell is ... Spear Education to participate in a specialized workshop. Of the ... the top 10% and those willing to sacrifice to be ...
(Date:3/6/2015)... San Diego, CA (PRWEB) March 06, 2015 ... study findings continue to be discussed, Ford & Associates ... wake of a January 2015 filed lawsuit: Verduzco v. ... Court, Northern District of California. , “In light ... those who have used Benicar to evaluate and explore ...
(Date:3/5/2015)... (PRWEB) March 06, 2015 In 2014, ... being first–in-class. AstraZeneca tops the list scoring 4 drug ... over 25% of all FDA approved drug products, followed ... mechanisms such as anti-PCSK9, anti-PD1 and CDK inhibitors keep ... approved by the FDA to treat metastatic melanoma, and ...
(Date:3/5/2015)... This week, 60 Minutes ... laminate flooring products, initiating widespread concern from homeowners. ... materials made primarily from bamboo, stands behind their ... flooring products for volatile organic compounds (VOCs) through ... (BMH). Results from formaldehyde emissions testing show ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 ... forward in a Pennsylvania mass tort litigation currently ... where a jury has begun hearing testimony in ... the atypical antipsychotic medication can cause gynecomastia, or ... case in question was filed on behalf of ...
Breaking Medicine News(10 mins):Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... 22 ResMed Inc. (NYSE: RMD ), announced ... its results for the third quarter and nine months of ... with ResMed,s results will be issued after 1:00 p.m. Pacific ... webcast to review its results, market trends, and future outlook.The ...
... study finds older people taking NSAIDs more likely to suffer ... suggested that older people who want to avoid Alzheimer,s disease ... ibuprofen and naproxen, but a new study suggests that might ... ,Should I take these to prevent dementia?, the answer ...
... BALTIMORE, April 22 XLHealth, owner and operator of ... Advantage chronic condition Special Needs Plans, supports the proposed ... in the first of a series of round-table discussions ... The hearing,s focus on using the Medicare system as ...
... professional groups join with Congressional sponsors Reps. Israel, Brady ... access to IVIGWASHINGTON, April 22 Members ... introduction of new legislation - H.R. 2002, Medicare Patient ... inadequate Medicare reimbursements that currently restrict patient access to ...
... Study finds no link to condition that can increase ... Soy isoflavones don,t increase breast density, a new study ... increased breast density is associated with a higher risk ... that dietary factors, including isoflavones (estrogen-like plant compounds) might ...
... New York Times best-selling author and mother of five ... special family gathering to celebrate her status as a mom. Instead, ... seeking favors and just plain hard work. Novak,s 5th Annual Online ... May is a labor of love for her son who has ...
Cached Medicine News:Health News:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2009 Results 2Health News:Painkillers May Not Protect Against Dementia 2Health News:Painkillers May Not Protect Against Dementia 3Health News:XLHealth Statement on Senate Finance Committee Roundtable on Healthcare Reform 2Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 2Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 3Health News:New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin 4Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 2Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 3Health News:NY Times Best-Selling Author Brenda Novak Gives Annual Mother's Day Gift of Hope to Diabetic Son and Others 4
4 megapixel zoom digicam with a 4x optical zoom, Effective pixels:4.0 million CCD:1/1.8-in. type (4.13 million total pixels), Max Image size:2272 (2,272 x 1,704 pixels), Lens:4x Zoom-Nikkor; f = 7.85...
... Gene Tech acclaimed GT-CAPTURE digital camera ... most manufacturers microscope such as Olympus, Leica, ... data base and transferring images over the ... 1/1.8-in. CCD and a performance-proven Nikkor lens. ...
... The DN100 is a superb stand-alone ... high resolution images from local or remote ... fast and easy. The camera operates independently ... PC or special software required to capture ...
... systems for very low light levels. Both ... the most demanding cases, we recommend our ... high resolution (1 million pixels), and cryogenic ... use, achieves ultra-cold temperatures without liquid nitrogen, ...
Medicine Products: